Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Will 68Ga PSMA-radioligands be the only choice for nuclear medicine in prostate ...
Journal Information
Vol. 37. Issue 2.
Pages 103-109 (March - April 2018)
Download PDF
More article options
Vol. 37. Issue 2.
Pages 103-109 (March - April 2018)
Special collaboration
DOI: 10.1016/j.remnie.2017.10.029
Will 68Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update
¿Constituirán en el futuro los radioligandos de 68Ga-PSMA la única elección de la Medicina Nuclear para el cáncer de próstata? Actualización clínica
Vincenzo Cuccurulloa,
Corresponding author
, Giuseppe Danilo Di Stasioa, Laura Evangelistab, Andrea Ciarmielloc, Luigi Mansid
a Nuclear Medicine Unit, Department of Clinical and Experimental Internistic “F. Magrassi – A. Lanzara” – University of Campania Luigi Vanvitelli, Napoli, Italy
b Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto (IOV–IRCCS), Padova, Italy
c Department of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy
d Interuniversity Research Centre on Sustainable Development (CIRPS), Roma-Napoli, Italy
Article information
Full Text
Download PDF
Tables (2)
Table 1. Diagnostic tools and suggested indications.
Table 2. The most important radiotracers proposed in patients with PCa.
Show moreShow less

Prostate Cancer (PCa) represents the most common malignant tumor in men but according to the European Association of Urology (EAU) guidelines, a mass screening for PCa diagnosis should not be performed due to over-diagnosis and over-treatment related problems. An early clinical diagnosis is possible, mainly based on digital rectal examination and Prostatic Specific Agent (PSA) testing. However, the only mandatory test to define the presence of PCa is ultrasound guided-biopsy, obtained on multiple samples, which has also a high prognostic value. In this context, diagnostic imaging plays an important role as confirmed by EAU that in a 2016 update of their guidelines on PCa stated the importance of Positron Emission Tomography (PET) with 11C- or 18F-choline combined with computed tomography (CT) to identify local relapse, lymph node involvement and metastatic spread at all stages. Consequently, in 2017, the European Association of Nuclear Medicine (EANM) together with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) published new guidelines for 68Ga-Prostate Specific Membrane Antigen (PSMA) PET/CT to help physicians in the recommendation, execution and interpretation of PET/CT scans in patients with PCa. Thus, the aim of this “evidence paper” is to define the current diagnostic algorithm in PCa in order to increase the general level of confidence in approaching such a crucial topic.

Prostate cancer

El Cáncer de Próstata (CaP) representa el tumor maligno más frecuente en los varones pero, según las directrices de la European Association of Urology (EAU) no deben realizarse cribados masivos para el diagnóstico de CaP debido a problemas relacionados con el sobre-diagnóstico y sobre-tratamiento. El diagnóstico clínico precoz es posible, principalmente basado en el tacto rectal y la determinación del Antígeno Prostático Específico (PSA). Sin embargo, el único test que puede determinar la presencia de un CaP es la biopsia guiada por ecografía, obteniendo múltiples muestras, la cual tiene un elevado valor pronóstico. En este contexto, la imagen diagnóstica juega un importante papel tal como lo confirmó la EAU, que en una actualización de 2016 de su guía clínica sobre CaP estableció la importancia de la Tomografía por Emisión de positrones (PET) con 11C- o 18F-colina combinada con la Tomografía Computarizada (TC) para individualizar la recidiva local, la afectación de ganglios linfáticos y la diseminación metastásica en todos los estadios. En consecuencia, en 2017, la European Association of Nuclear Medicine (EANM) junto con la Society of Nuclear Medicine and Molecular Imaging (SNMMI) compartieron nuevas directrices para la PET/TC con 68Ga-Antígeno de Membrana Prostático Específico (PSMA) para ayudar a los médicos en la recomendación, realización e interpretación de los estudios PET/TC en pacientes con CaP. De esta manera, el objetivo de este “artículo de evidencia” es definir el algoritmo diagnóstico actual en el CaP para incrementar el nivel de confianza global en el enfoque de un tema tan crucial.

Palabras clave:
Cáncer de Próstata


These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos